(VIANEWS) – Shares of INVENTIVA (CAC 40: IVA.PA) dropped by a staggering 28.57% in 21 sessions from €5.11 to €3.65 at 14:08 EST on Thursday, after three consecutive sessions in a row of losses. CAC 40 is dropping 0.28% to €7,110.96, after three consecutive sessions in a row of gains.
About INVENTIVA
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Earnings Per Share
As for profitability, INVENTIVA has a trailing twelve months EPS of €-0.992.
Volume
Today’s last reported volume for INVENTIVA is 7184 which is 87.11% below its average volume of 22662.
More news about INVENTIVA (IVA.PA).
